Latest From MaxCyte Inc.
All-stock transaction combines privately held Oncternal with GTx, which had been considering its strategic alternatives. Biogen acquires gene therapy biotech Nightstar, MaxCyte and Kite expand their CAR-T partnership.
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
Industry and academic representatives shared viewpoints at Biotech Week Boston in September 2018, including what is unique about deal-making in the cell and gene field.
CRISPR Therapeutics and Vertex initiated the first human study of CRISPR gene-editing technology with an industry sponsor, following an investigator-sponsored study initiated in China two years ago. These are not the first gene-editing trials, but they're important milestones for the CRISPR field.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Large Molecule
- Synthesis Technologies, Production Processes
- Medical Devices
- Drug Delivery
- Therapeutic Areas
- TheraMed Inc.
- North America
- Parent & Subsidiaries
- MaxCyte Inc.
- Senior Management
Douglas A Doerfler, Pres. & CEO
Ronald Holtz, CFO
Deborah K Bowes, EVP, Bus. & Strategic Dev.
Madhusudan Peshwa, PhD, CSO, EVP, Cellular Therapies
Thomas M Ross, EVP, Global Sales
- Contact Info
Phone: (301) 944-1700
22 Firstfield Road
Gaithersburg, MD 20878
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.